![Sunil Rajanikant Mehta](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 58 M $ au 31/07/2026
Mr. Sunil Rajanikant Mehta is an Executive Director & Executive Director-Projects at Emcure Pharmaceuticals Ltd. He is on the Board of Directors at Gennova Biopharmaceuticals Ltd. and Emcure Pharmaceuticals Ltd. He received his undergraduate degree from the University of Pune and an MBA from the Institute of Management, Development & Research.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2025 | 2 847 012 ( 1,5% ) | 58 M $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EMCURE PHARMACEUTICALS LIMITED | Directeur/Membre du Conseil | 05/06/2013 |
Gennova Biopharmaceuticals Ltd.
 Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in biotechnology research for biosimilars, vaccines and monoclonal antibodies using recombinant DNA technology | Directeur/Membre du Conseil | 19/06/2001 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
University of Pune
 University of Pune Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Institute of Management, Development & Research
 Institute of Management, Development & Research Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Emcure Pharmaceuticals Ltd.
 Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Engages in developing, manufacturing and marketing of pharmaceutical products | Health Technology |
Gennova Biopharmaceuticals Ltd.
Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in biotechnology research for biosimilars, vaccines and monoclonal antibodies using recombinant DNA technology | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
